Your decision, not a generic summary.
An investment decision may depend on a narrow scientific uncertainty: whether a finding replicated, whether an endpoint is relevant or whether a listed asset can be evaluated and commercialized. The proposed Karam deliverable is scientific and commercial evidence to inform diligence, not an investment recommendation or a legal opinion.
Where a scoped engagement can help.
Before an investment committee
Specify the asset and the scientific assumption most likely to change the decision.
Before a license commitment
Separate the evidence of performance from the availability, scope and restrictions of the rights.
Between major decisions
Track material changes to the thesis rather than treating every new paper as equal.
What to bring.
The asset or target, intended decision, time limit, existing nonconfidential materials and the role of your legal and technical advisers.
How to compare a proposal.
A useful report makes the strongest counterargument visible. It should distinguish a sponsor announcement, a peer-reviewed finding and independent replication, and say what has not been inspected.
Example inquiry: “Which scientific assumption in this licensing opportunity is least supported, and what diligence would resolve it?”